# Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab

> **NCT01544595** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 1147 (actual)

## Conditions studied

- Moderate to Severe Plaque-type Psoriasis

## Interventions

- **DRUG:** Secukinumab (AIN457)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01544595
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06-19
- **Primary completion:** 2017-06-26
- **Final completion:** 2017-06-26
- **Target enrollment:** 1147 (ACTUAL)
- **Last updated:** 2018-12-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01544595

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01544595, "Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01544595. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*